You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firm plans to use $561 million of the net proceeds to fund the majority of its planned $591 million acquisition of Oxford Immunotec.
The firm plans to use the proceeds to fund the redemption of senior notes due in 2022 and for general corporate purposes.
The firm expects to raise $75 million from the senior notes offering and approximately $25 million from the public offering.
The firm plans to raise $25 million in a public offering of shares of its common stock and $75 million in a senior notes offering to institutional buyers.
The company will use a portion of the proceeds to enter into capped call transactions and the remainder for various corporate activities.
The company said it intends to use proceeds for general corporate purposes, including working capital and refinancing of outstanding indebtedness.
The notes are general senior unsecured obligations of Hologic guaranteed by certain domestic subsidiaries and expire on Feb. 15, 2029.
Hologic intends to use the proceeds of the offering and available cash to refinance its existing 4.375 percent senior unsecured notes due in 2025.
The company said that dried blood-spot sampling improves access to HIV diagnostic testing and care, particularly among HIV-infected people living in remote areas.
The company plans to use the funds for general corporate purposes, including, together with cash on hand, to repay borrowings under its term loan facility.